A review of the available information was performed.The manufacturing records for the onxace-23 sn [serial number] (b)(4) were reviewed and it was confirmed that all records were controlled, available for review, and met all specifications.All lots passed functional testing and met release specifications.Additional information received indicated that the patient (dob (b)(6) 1952) was implanted with an onxace-23, sn (b)(4) on (b)(6) 2018.The only other information available was that the patient had endocarditis.A definitive cause for the patient death cannot be determined based on the limited available information, however, it is likely related to sequelae of endocarditis and the trauma of surgery.The instructions for use [ifu] for the on-x valve lists endocarditis as a possible complication of mechanical heart valve replacement and includes the possibility of reoperation and/or explantation and death.Historically, endocarditis occurs at a rate of 1.2%patient-year for rigid heart valves [iso 5840:2005].A definitive cause for the patient death cannot be determined based on the limited available information.There is no indication that the on-x valve had any relationship to the patient death.This event does not identify additional hazards or modify the probability and severity of existing hazards.No further action is required.This report is being submitted as required by federal regulations and does not constitute an admission that the device caused or contributed to the reported event.Furthermore, this report reflects the event as alleged by the complainant and does not imply that the information reported to cryolife is accurate or has been confirmed by cryolife.
|